

PATIENT INFORMATION

<u>[1] Patient Name</u>	<u>[2] Date of Birth</u>	<u>[3] Height</u>	<u>[4] Weight</u>
<u>[5] Patient Address</u>	<u>[6] Patient Telephone #</u>	<u>[7] Patient Mobile #</u>	
<u>[8] Referring Provider</u>	<u>[9] Provider Telephone #</u>	<u>[10] Provider Fax#</u>	

[11] SIGNS AND SYMPTOMS (REQUIRED)

Type of cancer Histologically Proven Suspected

Please check Radiopharmaceutical

FDG DETECTNET

AXUMIN PYLARIFY

CERIANNA

CPT Codes
If provided a specific CPT code, please provide.

INSURANCE INFORMATION

[12] Primary Insurance [13] Subscribers Insurance ID #

Secondary Insurance Insurance Prior Authorization #

CMS/APPROPRIATE USE CRITERIA (FOR MEDICARE PART B PATIENTS ONLY)

<u>NPI#</u>	<u>Name of CDSM Consulted (software used)</u>	Determination Result (check one): <input type="checkbox"/> 1) Adheres to <input type="checkbox"/> 2) Does Not Adhere to <input type="checkbox"/> 3) Not Applicable
-------------	---	--

[14] (Check ONE and fill out corresponding section completely)

Initial Treatment Strategy

Diagnosis: Abnormal finding of _____
Based on _____

Check one

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent,

Initial Staging: of confirmed newly diagnosed cancer

Check one

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent.

Other (e.g., Alzheimer's Disease). Please list reason for scan here:

Subsequent Treatment Strategy

Restaging: (after the completion of treatment)

Check one

Status post the completion of treatment for the purpose of detecting residual disease
Last date of treatment: _____
Type of treatment: _____

Detecting suspected recurrence, or metastasis of previously treated cancer:
Site of suspected recurrence / metastasis: _____
Based on: _____

Determine the extent of a known recurrence.
Confirmed by: _____

PET/CT is being used to potentially replace one or more imaging studies that (1) is being utilized to determine extent of known recurrence of (2) provided insufficient information for the clinical management of the patient.

Monitoring Tumor Response: During Treatment

Check one

Chemotherapy Radiotherapy Other (specify): _____

[15] PRESCREENING QUESTIONNAIRE

Pregnant: <input type="checkbox"/> Y <input type="checkbox"/> N Diabetes: <input type="checkbox"/> Y <input type="checkbox"/> N	Prior Studies/Treatment Previous: <input type="checkbox"/> CT <input type="checkbox"/> MRI <input type="checkbox"/> PET/CT Where: _____ When: _____ Pathology: <input type="checkbox"/> Y <input type="checkbox"/> N Where: _____ When: _____ Radiation Therapy: <input type="checkbox"/> Y <input type="checkbox"/> N Provider: _____ When: _____ Chemotherapy: <input type="checkbox"/> Y <input type="checkbox"/> N Provider: _____ When: _____
--	---

<u>[16] Authorized Treating Provider's Signature:</u> (Stamps Not Accepted)	<u>[17] NPI #</u>	<u>[18] Date</u>
---	-------------------	------------------